IWBI Celebrates Crossing the 1,000th WELL Registered Project Mark
The WELL Building Standard™ (WELL™) has marked a new milestone, crossing the 1,000 mark for projects that have enrolled in this premier global program that advances people’s health and well-being through better buildings and communities.
The distinction of being 1,000th to register for WELL is shared by two projects in the capital city of Germany.
Together totaling 1.25 million square feet, the two office projects in Berlin are being developed by EDGE Technologies, a subsidiary of OVG Real Estate, and supported by BuroHappold. The EDGE buildings in Berlin near Südkreuz Station and East Side Gallery are both WELL Core projects registered under WELL v2, with the aim of achieving ambitious requirements for healthy and sustainable working environments. EDGE Technologies already achieved Germany’s first WELL Precertification at the Gold level for its EDGE Grand Central Berlin, and the Netherlands’ first WELL Precertification at the Platinum level for its EDGE Olympic in Amsterdam.
After crossing this milestone in late September, WELL’s momentum continued as its registered projects count today stands at 1,025, and includes the addition of the first registered project on the African continent, as well as the addition of Indonesia as one of the now 37 countries where WELL is being used.
'The growth of WELL tells a powerful success story of positive global engagement and speaks to the universal need to support and advance human health every way we can, including through the buildings and spaces we inhabit every day,' said Rick Fedrizzi, Chairman and CEO of the International WELL Building Institute™ (IWBI™), which develops and delivers the popular rating system.
He added, “What we’re experiencing through this second wave of sustainability is the demand for buildings and communities that sit at the heart of what this global movement is all about – people. Because ‘proven performance’ is the unique hallmark of WELL, leadership companies and organizations around the world are making it their certification of choice. After all, when it comes to human health why just assume you’ll get the performance you intend when you can validate it for all the world to see?”
Launched in October 2014 after six years of research and development, WELL has become the premier global standard for buildings, interior spaces and communities seeking to implement, validate and measure features that support and advance human health and wellness.
Earlier this spring, IWBI unveiled the WELL v2™ pilot, the next version of the pioneering rating system, which includes a full suite of enhancements that advance its global aim to build a healthier future for all.
A truly global rating system, WELL encompasses more than 190 million square feet of real estate projects in 37 countries worldwide. From major markets like China, the United States, Australia, France, the United Kingdom and Canada, to developing countries such as India, Brazil, Thailand and Colombia, the WELL Building Standard has resonated worldwide for its holistic approach to helping improve health and well-being for everyone inside the buildings. The program has also helped to spur innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns.
A dedicated community of practitioners and industry professionals from across the real estate, corporate, academic and public health spheres has taken shape alongside the global adoption of WELL. Today more than 3,500 people have successfully earned their WELL AP™ (Accredited Professional) credential, with nearly 2,300 more registered as part of the growing pool of individuals looking to develop and demonstrate their understanding of building strategies that put people at the center of decision making about the places we all live, work, learn and play.
About IWBI and WELL
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings and communities in ways that help people thrive. The WELL v2 pilot is a recently launched version of its popular WELL Building Standard, and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI convenes and mobilizes the global wellness real estate community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. For more information about IWBI and WELL, please visit us here.
International WELL Building Institute
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an